This is a $1,099,999.92 Phase II Small Business Innovation Research (SBIR) contract awarded by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to Consegna Pharma Inc., a self-certified small disadvantaged business. The contract is for research and development of a long-duration opioid overdose antagonist, which supports the agency's mission related to chemical and biological defense. This award follows a prior $167,421 SBIR Phase I contract with Consegna, also set aside for small businesses. Consegna Pharma is a specialty pharmaceutical company that develops long-acting injectable medications and has received additional federal funding, including grants from the National Institute on Drug Abuse, for research on treatments for substance abuse disorders and prevention of opioid overdoses.
Generated 3/30/24, 10:02 AM